In addition, Affymetrixexon microarray (Santa Clara, CA) was used to demonstrate that PRMT6-dependent gene signature influences long-term survival in breast cancer patients, which included (i) reduced level of the tumor inhibition, PTEN in breast cancer patient samples and increased PTEN mRNA expression after loss of PRMT6 in breast cancer cells, and (ii) differential splicing of genes involved in centrosome targeting, cell invasion, apoptosis, p21-interacting proteins, and other genes which involved in cell cycle regulation. This evidence concerns the gene CDKN1A and breast carcinoma.